Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
17
datasets available to search
ShareScore release 0.9.0
Dataset results
17 results for “BNT162b2 mRNA vaccine”
Raw Data for the article: Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients
<p>SARS‐CoV‐2 vaccine is considered the primary health strategy able to end the current COVID‐19 pandemic. This viral infection impacts more severely solid organ transplant recipients (SOTRs) than general population, but the effect of vaccination in this subgroup of immunosuppressed patients is not known due to their exclusion from vaccination trials. Preliminary reports suggest a lower antibody production after BNT162b2 Pfizer/BioNTech mRNA‐vaccine,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0001"> 1 </a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0002">2 </a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0003">3 </a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0004">4 </a>but no data are currently available on the elicited virus‐specific T cell responses.</p>
Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers
ClinicalTrials.gov study NCT05308680. IPD Sharing: NO. Countries: 1. Publications: 1.
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
ClinicalTrials.gov study NCT05465863. IPD Sharing: NO. Countries: 1. Publications: 1.
BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment
ClinicalTrials.gov study NCT04932863. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
ClinicalTrials.gov study NCT04649021. IPD Sharing: NO. Countries: 1. Publications: 1.
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil
ClinicalTrials.gov study NCT05403307. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL
ClinicalTrials.gov study NCT04862806. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
ClinicalTrials.gov study NCT05366322. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil
ClinicalTrials.gov study NCT05052307. IPD Sharing: NO. Countries: 1. Publications: 2.
CITE-seq of 6 patients treated with the Pfizer BioNTech BNT162b2 mRNA vaccine
GEO Series GSE171964. Homo sapiens. 92 samples. Type: Expression profiling by high throughput sequencing.
Response to mRNA vaccine BNT162b2 in hemodialysis patients
GEO Series GSE209985. Homo sapiens. 188 samples. Type: Expression profiling by high throughput sequencing.
Immune transcriptome in adult-onset Still’s disease with mild flare following administration of mRNA vaccine BNT162b2
GEO Series GSE198549. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
<p>Multiple formulations and technologies for vaccinating against SARS-CoV-2 exist but how the use of these in homologous or heterologous format impacts immunogenicity is far from clear. Here the authors compare a range of heterologous and homologous SARS-CoV-2 vaccination strategies and assess the induced humoral and cellular immune response.</p> <p>The following heterologous and homologous vaccination regimens were tested for immunogenicity and reactogenicity in a in a convenience cohort of 331 healthy individuals. </p> <p>ChAdOx1-nCoV-19 followed by BNT162b2 (n=66)</p> <p>ChAdOx1-nCoV-19 followed by mRNA-1273 (n=101)</p> <p>BNT162b2 followed by BNT162b2 (n=43)</p> <p>mRNA-1273 followed by mRNA-1273 (n=59)</p> <p>ChAdOx1-nCoV-19 followed by ChAdOx1-nCoV-19 (n=62)</p>
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273
ClinicalTrials.gov study NCT05420077. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
ClinicalTrials.gov study NCT04881396. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention.
<p>Dataset from Malavazos AE, Basilico S, Iacobellis G, Milani V, Cardani R, Boniardi F, Dubini C, Prandoni I, Capitanio G, Renna LV, Boveri S, Rigolini R, Carrara M, Spuria G, Cuppone T, D'acquisto A, Carpinelli L, Sacchi M, Morricone L, Secchi F, Costa E, Menicanti L, Nisoli E, Carruba M, Ambrogi F, Corsi Romanelli MM. Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention. Obesity (Silver Spring). 2021 Nov 30. doi: 10.1002/oby.23353. Epub ahead of print. PMID: 34850576.</p> <p>Abstract</p> <p><strong>Objective: </strong>The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2 specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals with AO to those without, discerning between individuals with or without prior infection.</p> <p><strong>Methods: </strong>IgG neutralizing antibodies against the Trimeric-complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, at one and three months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO.</p> <p><strong>Results: </strong>Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, p<0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p<0.001).</p> <p><strong>Conclusions: </strong>The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high-risk medical conditions including obesity and particularly to those with more prevalent abdominal obesity phenotype.</p>
Antibody responses to BNT162b2 mRNA vaccine: Infection-naïve individuals with abdominal obesity warrant attention
<p>Malavazos AE, Basilico S, Iacobellis G, Milani V, Cardani R, Boniardi F, Dubini C, Prandoni I, Capitanio G, Renna LV, Boveri S, Rigolini R, Carrara M, Spuria G, Cuppone T, D'acquisto A, Carpinelli L, Sacchi M, Morricone L, Secchi F, Costa E, Menicanti L, Nisoli E, Carruba M, Ambrogi F, Corsi Romanelli MM. Antibody responses to BNT162b2 mRNA vaccine: Infection-naïve individuals with abdominal obesity warrant attention. Obesity (Silver Spring). 2022 Mar;30(3):606-613. doi: 10.1002/oby.23353. Epub 2022 Feb 11. PMID: 34850576.</p> <p>Abstract</p> <p><strong>Objective: </strong>The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. SARS-CoV-2-specific antibody responses were evaluated after the first and second dose of the BNT162b2 mRNA vaccine, comparing the response of individuals with AO with the response of those without, and discerning between individuals with or without prior infection.</p> <p><strong>Methods: </strong>Immunoglobulin G (IgG)-neutralizing antibodies against the Trimeric complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, and at 1 and 3 months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO.</p> <p><strong>Results: </strong>Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared with those without AO (2.44-fold [95% CI: 2.22-2.63] vs. 1.82-fold [95% CI: 1.69-1.92], respectively, p < 0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p < 0.001).</p> <p><strong>Conclusions: </strong>The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high-risk medical conditions, including obesity, and particularly to those with a more prevalent AO phenotype.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.